Advanced or metastatic renal cell carcinoma (RCC) responds poorly to current combination therapies, as anti-angiogenic agents and immune checkpoint inhibitors fail to act in a spatiotemporally synchronized manner. Consequently, their...
Wang et al. (2026) studied this question.